Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00845702 · ClinicalTrials.gov registry record · Phase 3
Renal Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)
A Phase 3 study, sponsored by Guerbet.
- Terminated
- Registry status
- Phase 3
- Development phase
- 33
- Enrollment target
NCT00845702 is a Phase 3 study that was terminated before completion, run by Guerbet. The registered enrollment target is 33 participants.
The verdict
NCT00845702, a Phase 3 study, was terminated before completion, sponsored by Guerbet.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 33 participants
- Enrollment target
Study Summary
The study will evaluate the efficacy and safety of Dotarem enhanced MRA compared to TOF MRA in patients suffering from renal arterial disease.
Interventions
- DRUG Gadoterate meglumine (Dotarem)
- OTHER Time of Flight Magnetic Resonance Angiography
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2009-04 |
| Est. Completion | 2010-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00845702
The ClinicalTrials.gov registry entry for NCT00845702 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Guerbet, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Gadoterate meglumine (Dotarem) is the first listed.
NCT00845702 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00845702 about?
NCT00845702 is a clinical study titled "Renal Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)". The study will evaluate the efficacy and safety of Dotarem enhanced MRA compared to TOF MRA in patients suffering from renal arterial disease.
What is the current status of trial NCT00845702?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 33 participants. The study started on 2009-04. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00845702?
The interventions under investigation include: Gadoterate meglumine (Dotarem) (DRUG), Time of Flight Magnetic Resonance Angiography (OTHER).
Who is sponsoring clinical trial NCT00845702?
This trial is sponsored by Guerbet, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.